dc.contributor.author | Kühnl, A | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Hutka, M | |
dc.contributor.author | Peckitt, C | |
dc.contributor.author | Rozati, H | |
dc.contributor.author | Morano, F | |
dc.contributor.author | Chong, I | |
dc.contributor.author | Gillbanks, A | |
dc.contributor.author | Wotherspoon, A | |
dc.contributor.author | Harris, M | |
dc.contributor.author | Murray, T | |
dc.contributor.author | Chau, I | |
dc.date.accessioned | 2019-03-04T16:17:36Z | |
dc.date.issued | 2018-01-01 | |
dc.identifier.citation | BMC hematology, 2018, 18 pp. 19 - ? | |
dc.identifier.issn | 2052-1839 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3132 | |
dc.identifier.eissn | 2052-1839 | |
dc.identifier.doi | 10.1186/s12878-018-0109-0 | |
dc.description.abstract | BACKGROUND: In patients presenting with peripheral lymphadenopathy, it is critical to effectively identify those with underlying cancer who require urgent specialist care. METHODS: We analyzed a large dataset of 1000 consecutive patients with unexplained lymphadenopathy referred between 2001 and 2009 to the Royal Marsden Hospital (RMH) rapid access lymph node diagnostic clinic (LNDC). RESULTS: Cancer was diagnosed in 14% of patients. Factors predictive for malignant disease were male sex, age, supraclavicular and multiple site involvement. Cancer-associated symptoms were present for a median of 8 weeks. The median time from referral to start of cancer therapy was 53 days. Fine needle aspiration (FNA) was performed in 83% of patients with malignancies. Sensitivity and specificity of FNA were limited (50 and 87%, respectively for any malignancy; 30 and 79%, respectively for lymphoma). The vast majority of cancer patients received diagnostic biopsies on the basis of suspicious clinical and ultrasound findings; the FNA result contributed to establishing the diagnosis in only 4 cases. CONCLUSIONS: In conclusion, we demonstrate that Oncologist-led rapid access clinics are successful concepts to assess patients with unexplained lymphadenopathy. Our data suggest that a routine use of FNA should be reconsidered in this setting. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 19 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-06-25 | |
rioxxterms.versionofrecord | 10.1186/s12878-018-0109-0 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | BMC hematology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Ashworth Collaborators | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 18 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
icr.researchteam | Ashworth Collaborators | |
dc.contributor.icrauthor | Chong, Yu-Shing | |